

## APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS

The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99–499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological profiles for each substance included on the priority list of hazardous substances; and assure the initiation of a research program to fill identified data needs associated with the substances.

The toxicological profiles include an examination, summary, and interpretation of available toxicological information and epidemiologic evaluations of a hazardous substance. During the development of toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are used by ATSDR health assessors to identify contaminants and potential health effects that may be of concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or action levels.

MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor approach. They are below levels that might cause adverse health effects in the people most sensitive to such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and chronic (365 days and longer) durations and for the oral and inhalation routes of exposure. Currently, MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end point considered to be of relevance to humans. Serious health effects (such as irreparable damage to the liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level above the MRL does not mean that adverse health effects will occur.

## APPENDIX A

MRLs are intended only to serve as a screening tool to help public health professionals decide where to look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health principle of prevention. Although human data are preferred, MRLs often must be based on animal studies because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes that humans are more sensitive to the effects of hazardous substance than animals and that certain persons may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that have been shown to be nontoxic in laboratory animals.

Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the Division of Toxicology, expert panel peer reviews, and agency-wide MRL Workgroup reviews, with participation from other federal agencies and comments from the public. They are subject to change as new information becomes available concomitant with updating the toxicological profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels. For additional information regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop F-32, Atlanta, Georgia 30333.

## APPENDIX A

**MINIMAL RISK LEVEL (MRL) WORKSHEET**

Chemical Name: Ammonia  
CAS Number: 7664-41-7  
Date: July 2004  
Profile Status: Third Draft Post-Public  
Route:  Inhalation  Oral  
Duration:  Acute  Intermediate  Chronic  
Graph Key: 14  
Species: Human

Minimal Risk Level: 1.7  mg/kg/day  ppm

Reference: Verberk MM. 1977. Effects of ammonia in volunteers. Int Arch Occup Environ Health 39:73-81.

Experimental design: The study examined the effects of exposure to ammonia in a group of 16 volunteers. Eight of them (experts) knew the effects of ammonia from the literature, but had had no personal contact, whereas the remaining eight subjects (non-experts) were students from a non-science faculty and were not familiar with ammonia or experiments in laboratory situations. All members of a group were exposed on the same day to one of the concentrations tested (50, 80, 110, or 140 ppm). The testing was repeated with a 1-week interval. Immediately before and after exposure, vital capacity, forced expiratory volume, and forced inspiratory volume were measured. During exposure, each subject recorded subjective feelings every 15 minutes as no sensation (0), just perceptible (1), distinctly perceptible (2), nuisance (3), offensive (4), or unbearable (5). No statistical analysis was performed and there was no group exposed to air only. A few weeks after the experiments, the subjects were tested to measure (pre-existing) non-specific reactivity of the airways to exogenous stimuli.

Effects noted in study and corresponding doses: None of the participants was hypersusceptible to non-specific irritants. Results of the pulmonary function tests after exposure were not statistically significantly different from pre-exposure values. For the non-experts, there was a clear increase in the number of reported symptoms for smell, eye irritation, throat irritation, cough, and general discomfort as the exposure concentration increased. The latter was not as clear for the experts. The number of symptoms recorded with a score >3 (nuisance) for smell, eye irritation, nose, throat, and urge to cough for the 50, 80, 110, and 140 ppm exposure groups was 2, 2, 7, and 11, respectively, for the experts and 6, 12, 18, and 29, respectively, for the non-experts. It should also be mentioned that the subjective responses appeared more pronounced in the non-expert group than in the expert group.

Dose and end point used for MRL derivation: 50 ppm for mild irritation to the eyes, nose, and throat in humans exposed to ammonia gas for 2 hours.

Because the effects observed were local irritation effects, they were not time-dependent (but rather concentration-dependent), an adjustment to 24-hour exposure was not necessary.

NOAEL  LOAEL

## APPENDIX A

Uncertainty Factors used in MRL derivation:

- [ X ] 3 for use of a minimal LOAEL
- [ ] 10 for extrapolation from animals to humans
- [ X ] 10 for human variability

Was a conversion used from ppm in food or water to a mg/body weight dose?

N/A

If an inhalation study in animals, list the conversion factors used in determining human equivalent dose:

N/A

Other additional studies or pertinent information which lend support to this MRL: Although the Verberk et al. (1977) study has limitations (no statistical analysis, subjective end points, no control group), it demonstrates that concentrations of 50 ppm ammonia can produce minimal discomfort in healthy members of the general population and therefore, should be avoided. Additional relevant information is provided by a study by Ferguson et al. (1977). In that study, a group of six healthy volunteers, not previously accustomed to working in an ammonia environment, were exposed 5 days/week to 25 ppm (2 hours/day), 50 ppm (4 hours/day), or 100 ppm (6 hours/day) of ammonia, or to 50 ppm of ammonia 6 hours/day for 6 weeks. End points monitored included subjective and objective measures of eye and throat irritation as well as pulse rate, respiration rate, pulmonary function (FVC, FEV), assessment of neurological function (reflex, balance, and coordination), and body weight. The exposure protocol consisted of a pre-exposure evaluation by a physician, 3 hours of exposure (this conflicts with exposure data on table 2 of the study and mentioned above), a mid-point physician's observation, lunch break, 3 additional hours of exposure, and a third physician's observation 30 minutes after exposure ceased. The conjunctiva and mucosa of the nose and throat were examined by a physician before and after each daily exposure and the degree of irritation noted was described as mild, moderate, or marked. Exposure to ammonia had no significant effect on the measures of respiratory function or in the neurological tests conducted. The results of the evaluations of irritation conducted by the physician showed no significant differences between the exposure groups, including the 0 ppm exposure group (pre-exposure). All subjects experienced some watering of the eyes and a sensation of dryness in the nose and throat and there was one observation of definite redness in the mucosa of the nose after a 6-hour exposure to 100 ppm during which time, there was an excursion to 200 ppm ammonia. No redness was observed in this subject the following morning. Throughout the study, the physician observed 6 cases of eye irritation, 20 of nose irritation, and 9 of throat irritation, and most cases appeared to have occurred the first week of the study during exposure to 50 ppm. It is difficult to determine in this study a NOAEL or LOAEL for irritation due to the different exposure durations experienced by the subjects, but it would appear that an exposure concentration of 100 ppm ammonia for 6 hours caused no significant changes in the vital functions measured and that 50 ppm can cause eye, nose, and throat irritation.

NIOSH (1974) reviewed 15 studies of case reports in which subjects were exposed to very high, but unquantified, concentrations of ammonia. The 15 reports provided a representative array of documented clinical findings including death, permanent eye lesions, and chronic respiratory symptoms, as well as acute lower and upper respiratory symptoms. The only quantitative information available was that a worker died 6 hours after estimated exposure to 10,000 ppm ammonia for an unspecified time (Mulder and Van der Zalm 1967). Studies with volunteers, also reviewed by NIOSH (1974), generally used concentrations of ammonia much higher than those in the studies by Verberk et al. (1977) or Ferguson et al. (1977) and/or exposure durations of only minutes. For example, exposure to a concentration of 500 ppm for 30 minutes caused respiratory irritation graded as severe by 2 out of 7 subjects (Silverman et al. 1949). Four out of 6 volunteers exposed to 50 ppm ammonia for 10 minutes graded the irritation as "moderate" and none described it as "discomforting" or "painful" (MacEwen et al. 1970). All of the

## APPENDIX A

subjects rated the odor as “highly penetrating” at 50 ppm and 3 subjects gave the same rating to 30 ppm. IBT (1973) exposed 10 subjects to 32, 50, 72, and 134 ppm for 5 minutes and the frequency of positive findings was as follows: at 32 ppm, 1 subject complained of dryness of the nose; at 50 ppm, 2 subjects complained of dryness of the nose; at 72 ppm, 3 subjects experienced eye irritation, 2 had nasal irritation, and 3 had throat irritation; and at 134 ppm, 5 subjects had signs of lacrimation, 5 had eye irritation, 7 had nasal irritation, 8 had throat irritation, and 1 had chest irritation.

Collectively, the available information from studies in humans supports the 50 ppm exposure level from the Verberk et al. (1977) study as a minimal LOAEL for irritation in acute studies. In general, studies in animals have used higher exposure concentrations. For ammonia, a corrosive irritant gas that affects the portal of entry and produces irritation of the eyes and respiratory tract, use of human data should be preferred over animal studies.

Agency Contact (Chemical Manager): Nickolette Roney, MPH

## APPENDIX A

**MINIMAL RISK LEVEL (MRL) WORKSHEET**

Chemical Name: Ammonia and Ammonium Compounds  
CAS Number: 7664-41-7  
Date: July 2004  
Profile Status: Third Draft Post Public  
Route:  Inhalation  Oral  
Duration:  Acute  Intermediate  Chronic  
Graph Key: 47  
Species: Humans

Minimal Risk Level: 0.1  mg/kg/day  ppm

Reference: Holness DL, Purdham JT, Nethercott JR. 1989. Acute and chronic respiratory effects of occupational exposure to ammonia. Am Ind Hyg Assoc J 50:646-650.

Experimental design: The study evaluated sense of smell, prevalence of respiratory symptoms (cough, bronchitis, wheeze, dyspnea, and others), eye and throat irritation, and lung function parameters (FVC, FEV<sub>1</sub>, FEV<sub>1</sub>/FVC, FEF<sub>50</sub>, and FEF<sub>75</sub>) in humans exposed for an average of 12.2 years in a soda ash plant (Holness et al. 1989). The cohort consisted of 52 workers and 35 controls. The subjects were assessed on two workdays: on the first workday of their workweek and on the last workday of their workweek. Spirometry was performed at the beginning and end of each work shift, so that each worker had four tests done. To determine the exposure levels, exposed and control workers were sampled over one work shift; the average sample collection period was 8.4 hours. All of the participants in the study were males.

Effects noted in study and corresponding doses: Analysis of the results showed no significant differences in the prevalence of reported symptoms, but the exposed workers reported that exposure in the plant aggravated some of their reported symptoms (cough, wheeze, nasal complaints, eye irritation, and throat discomfort). Odor threshold was not affected by exposure to ammonia and there were no significant differences in baseline lung functions between exposed and control subjects. Analysis of each worker separately showed no significant relationship between the level of ammonia exposure and changes in lung function. Also, when the workers were divided into groups of individuals that were exposed to low (<6.25 ppm), medium (6.25–12.5 ppm), and high (>12.5 ppm) ammonia levels, no significant association was found between reporting of symptoms, decline in baseline function, or increasing decline in function over the work shift and exposure to ammonia. Furthermore, no association was evident between increasing years of exposure and decreasing lung function. However, the power of the indices of both level and length of exposure is low because only eight workers were in areas with relatively high ammonia exposure.

The MRL was calculated by adjusting the NOAEL of 9.2 ppm (the mean TWA exposure concentration) for continuous exposure (9.2 x 8/24 hours x 5/7 days) and dividing by an uncertainty factor of 10 for the protection of sensitive individuals. A modifying factor of 3 was used for the lack of reproductive and developmental studies.

Dose and end point used for MRL derivation: 9.2 ppm for no significant alterations in lung function in chronically exposed workers.

NOAEL  LOAEL

## APPENDIX A

Uncertainty Factors used in MRL derivation:

- 10 for use of a LOAEL
- 10 for extrapolation from animals to humans
- 10 for human variability

Modifying Factors used in MRL derivation:

- 3 for lack of reproductive and developmental studies

Was a conversion used from ppm in food or water to a mg/body weight dose?

N/A.

If an inhalation study in animals, list the conversion factors used in determining human equivalent dose:

N/A.

Other additional studies or pertinent information which lend support to this MRL: Earlier studies summarized by NIOSH (1974) found that workers accustomed to 20 ppm ammonia did not complain of irritation symptoms, but showed slight redness in the conjunctiva. Those not accustomed had eye and respiratory discomfort and irritation. Another report stated that air levels below 5 ppm were associated with barely noticeable eye irritation. In yet an additional report, concentrations of 15–28 ppm in the work area produced slight eye irritation. More recent data reported respiratory effects associated with chronic-duration exposure to pollutants, including ammonia, in livestock confinement buildings and an increase in respiratory symptoms (such as bronchial reactivity/hyperresponsiveness, inflammation, cough, wheezing, or shortness of breath) and/or a decrease in lung function (such as forced expiratory volume in the first second [FEV<sub>1.0</sub>], maximum expiratory flow rates [MEF<sub>50</sub> and MEF<sub>75</sub>], and maximal mid-expiratory flow rate [MMEF]) in farmers exposed to ammonia levels of 2.3–20.7 ppm (Choudat et al. 1994; Cormier et al. 2000; Donham et al. 1995, 2000; Heederik et al. 1990; Reynolds et al. 1996; Vogelzang et al. 1997, 2000). The farmers were also exposed to other possible respiratory toxins, such as dust and endotoxins. A cross-sectional study of male workers at two fertilizer factories in Saudi Arabia showed a significant association between exposure to ammonia gas and respiratory symptoms and bronchial asthma (Ballal et al. 1998). No continuous exposure levels could be calculated for these workers because the number of days worked per week was not provided. There were no chronic-duration inhalation studies in animals.

Agency Contact (Chemical Manager): Nickolette Roney, MPH





## APPENDIX B. USER'S GUIDE

### Chapter 1

#### Public Health Statement

This chapter of the profile is a health effects summary written in non-technical language. Its intended audience is the general public, especially people living in the vicinity of a hazardous waste site or chemical release. If the Public Health Statement were removed from the rest of the document, it would still communicate to the lay public essential information about the chemical.

The major headings in the Public Health Statement are useful to find specific topics of concern. The topics are written in a question and answer format. The answer to each question includes a sentence that will direct the reader to chapters in the profile that will provide more information on the given topic.

### Chapter 2

#### Relevance to Public Health

This chapter provides a health effects summary based on evaluations of existing toxicologic, epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, weight-of-evidence discussions for human health end points by addressing the following questions:

1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous waste sites?

The chapter covers end points in the same order that they appear within the Discussion of Health Effects by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect. Human data are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). *In vitro* data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered in this chapter.

The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if derived) and the end points from which they were derived are indicated and discussed.

Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public health are identified in the Chapter 3 Data Needs section.

#### Interpretation of Minimal Risk Levels

Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not

## APPENDIX B

meant to support regulatory action, but to acquaint health professionals with exposure levels at which adverse health effects are not expected to occur in humans.

MRLs should help physicians and public health officials determine the safety of a community living near a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water. MRLs are based largely on toxicological studies in animals and on reports of human occupational exposure.

MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2, "Relevance to Public Health," contains basic information known about the substance. Other sections such as Chapter 3 Section 3.9, "Interactions with Other Substances," and Section 3.10, "Populations that are Unusually Susceptible" provide important supplemental information.

MRL users should also understand the MRL derivation methodology. MRLs are derived using a modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.

To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, represents the most sensitive human health effect for a given exposure route and duration. ATSDR cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available for all potential systemic, neurological, and developmental effects. If this information and reliable quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive species (when information from multiple species is available) with the highest no-observed-adverse-effect level (NOAEL) that does not exceed any adverse effect levels. When a NOAEL is not available, a lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor (UF) of 10 must be employed. Additional uncertainty factors of 10 must be used both for human variability to protect sensitive subpopulations (people who are most susceptible to the health effects caused by the substance) and for interspecies variability (extrapolation from animals to humans). In deriving an MRL, these individual uncertainty factors are multiplied together. The product is then divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure (LSE) tables.

## Chapter 3

### Health Effects

#### Tables and Figures for Levels of Significant Exposure (LSE)

Tables and figures are used to summarize health effects and illustrate graphically levels of exposure associated with those effects. These levels cover health effects observed at increasing dose concentrations and durations, differences in response by species, MRLs to humans for noncancer end points, and EPA's estimated range associated with an upper-bound individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to locate data for a specific exposure scenario. The LSE tables and figures should always be used in conjunction with the text. All entries in these tables and figures represent studies that provide reliable, quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).

The legends presented below demonstrate the application of these tables and figures. Representative examples of LSE Table 3-1 and Figure 3-1 are shown. The numbers in the left column of the legends correspond to the numbers in the example table and figure.

## APPENDIX B

**LEGEND****See Sample LSE Table 3-1 (page B-6)**

- (1) Route of Exposure. One of the first considerations when reviewing the toxicity of a substance using these tables and figures should be the relevant and appropriate route of exposure. Typically when sufficient data exist, three LSE tables and two LSE figures are presented in the document. The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively). LSE figures are limited to the inhalation (LSE Figure 3-1) and oral (LSE Figure 3-2) routes. Not all substances will have data on each route of exposure and will not, therefore, have all five of the tables and figures.
- (2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15–364 days), and chronic (365 days or more)—are presented within each relevant route of exposure. In this example, an inhalation study of intermediate exposure duration is reported. For quick reference to health effects occurring from a known length of exposure, locate the applicable exposure period within the LSE table and figure.
- (3) Health Effect. The major categories of health effects included in LSE tables and figures are death, systemic, immunological, neurological, developmental, reproductive, and cancer. NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. Systemic effects are further defined in the "System" column of the LSE table (see key number 18).
- (4) Key to Figure. Each key number in the LSE table links study information to one or more data points using the same key number in the corresponding LSE figure. In this example, the study represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL (also see the two "18r" data points in sample Figure 3-1).
- (5) Species. The test species, whether animal or human, are identified in this column. Chapter 2, "Relevance to Public Health," covers the relevance of animal data to human toxicity and Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics. Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent human doses to derive an MRL.
- (6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure regimens are provided in this column. This permits comparison of NOAELs and LOAELs from different studies. In this case (key number 18), rats were exposed to "Chemical x" via inhalation for 6 hours/day, 5 days/week, for 13 weeks. For a more complete review of the dosing regimen, refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 1981).
- (7) System. This column further defines the systemic effects. These systems include respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems. In the example of key number 18, one systemic effect (respiratory) was investigated.
- (8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system,

## APPENDIX B

which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see footnote "b").

- (9) **LOAEL.** A LOAEL is the lowest dose used in the study that caused a harmful health effect. LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help readers identify the levels of exposure at which adverse health effects first appear and the gradation of effects with increasing dose. A brief description of the specific end point used to quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm. MRLs are not derived from Serious LOAELs.
- (10) **Reference.** The complete reference citation is given in Chapter 9 of the profile.
- (11) **CEL.** A CEL is the lowest exposure level associated with the onset of carcinogenesis in experimental or epidemiologic studies. CELs are always considered serious effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report doses not causing measurable cancer increases.
- (12) **Footnotes.** Explanations of abbreviations or reference notes for data in the LSE tables are found in the footnotes. Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to derive an MRL of 0.005 ppm.

**LEGEND**

**See Sample Figure 3-1 (page B-7)**

LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the reader quickly compare health effects according to exposure concentrations for particular exposure periods.

- (13) **Exposure Period.** The same exposure periods appear as in the LSE table. In this example, health effects observed within the acute and intermediate exposure periods are illustrated.
- (14) **Health Effect.** These are the categories of health effects for which reliable quantitative data exists. The same health effects appear in the LSE table.
- (15) **Levels of Exposure.** Concentrations or doses for each health effect in the LSE tables are graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log scale "y" axis. Inhalation exposure is reported in mg/m<sup>3</sup> or ppm and oral exposure is reported in mg/kg/day.
- (16) **NOAEL.** In this example, the open circle designated 18r identifies a NOAEL critical end point in the rat upon which an intermediate inhalation exposure MRL is based. The key number 18 corresponds to the entry in the LSE table. The dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of 0.005 ppm (see footnote "b" in the LSE table).
- (17) **CEL.** Key number 38m is one of three studies for which CELs were derived. The diamond symbol refers to a CEL for the test species-mouse. The number 38 corresponds to the entry in the LSE table.

## APPENDIX B

- (18) Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the cancer dose response curve at low dose levels ( $q_1^*$ ).
- (19) Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.

## SAMPLE

1 →

Table 3-1. Levels of Significant Exposure to [Chemical x] – Inhalation


Key to figure <sup>a</sup>	Species	Exposure frequency/ duration	System	NOAEL (ppm)	LOAEL (effect)		Reference
					Less serious (ppm)	Serious (ppm)	
2 → INTERMEDIATE EXPOSURE							
	5	6	7	8	9		10
3 → Systemic	↓	↓	↓	↓	↓		↓
4 → 18	Rat	13 wk 5 d/wk 6 hr/d	Resp	3 <sup>b</sup>	10 (hyperplasia)		Nitschke et al. 1981
CHRONIC EXPOSURE							
Cancer					11		
					↓		
38	Rat	18 mo 5 d/wk 7 hr/d			20	(CEL, multiple organs)	Wong et al. 1982
39	Rat	89–104 wk 5 d/wk 6 hr/d			10	(CEL, lung tumors, nasal tumors)	NTP 1982
40	Mouse	79–103 wk 5 d/wk 6 hr/d			10	(CEL, lung tumors, hemangiosarcomas)	NTP 1982

12 →

<sup>a</sup> The number corresponds to entries in Figure 3-1.<sup>b</sup> Used to derive an intermediate inhalation Minimal Risk Level (MRL) of  $5 \times 10^{-3}$  ppm; dose adjusted for intermittent exposure and divided by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).

# SAMPLE

### Figure 3-1. Levels of Significant Exposure to [Chemical X] - Inhalation







**APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS**

ACGIH	American Conference of Governmental Industrial Hygienists
ACOEM	American College of Occupational and Environmental Medicine
ADI	acceptable daily intake
ADME	absorption, distribution, metabolism, and excretion
AED	atomic emission detection
AFID	alkali flame ionization detector
AFOSH	Air Force Office of Safety and Health
ALT	alanine aminotransferase
AML	acute myeloid leukemia
AOAC	Association of Official Analytical Chemists
AOEC	Association of Occupational and Environmental Clinics
AP	alkaline phosphatase
APHA	American Public Health Association
AST	aspartate aminotransferase
atm	atmosphere
ATSDR	Agency for Toxic Substances and Disease Registry
AWQC	Ambient Water Quality Criteria
BAT	best available technology
BCF	bioconcentration factor
BEI	Biological Exposure Index
BMD	benchmark dose
BMR	benchmark response
BSC	Board of Scientific Counselors
C	centigrade
CAA	Clean Air Act
CAG	Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS	Chemical Abstract Services
CDC	Centers for Disease Control and Prevention
CEL	cancer effect level
CELDS	Computer-Environmental Legislative Data System
CERCLA	Comprehensive Environmental Response, Compensation, and Liability Act
CFR	Code of Federal Regulations
Ci	curie
CI	confidence interval
CL	ceiling limit value
CLP	Contract Laboratory Program
cm	centimeter
CML	chronic myeloid leukemia
CPSC	Consumer Products Safety Commission
CWA	Clean Water Act
DHEW	Department of Health, Education, and Welfare
DHHS	Department of Health and Human Services
DNA	deoxyribonucleic acid
DOD	Department of Defense
DOE	Department of Energy
DOL	Department of Labor
DOT	Department of Transportation

## APPENDIX C

DOT/UN/ NA/IMCO	Department of Transportation/United Nations/ North America/International Maritime Dangerous Goods Code
DWEL	drinking water exposure level
ECD	electron capture detection
ECG/EKG	electrocardiogram
EEG	electroencephalogram
EEGL	Emergency Exposure Guidance Level
EPA	Environmental Protection Agency
F	Fahrenheit
F <sub>1</sub>	first-filial generation
FAO	Food and Agricultural Organization of the United Nations
FDA	Food and Drug Administration
FEMA	Federal Emergency Management Agency
FIFRA	Federal Insecticide, Fungicide, and Rodenticide Act
FPD	flame photometric detection
fpm	feet per minute
FR	Federal Register
FSH	follicle stimulating hormone
g	gram
GC	gas chromatography
gd	gestational day
GLC	gas liquid chromatography
GPC	gel permeation chromatography
HPLC	high-performance liquid chromatography
HRGC	high resolution gas chromatography
HSDB	Hazardous Substance Data Bank
IARC	International Agency for Research on Cancer
IDLH	immediately dangerous to life and health
ILO	International Labor Organization
IRIS	Integrated Risk Information System
K <sub>d</sub>	adsorption ratio
kg	kilogram
kgg	metric ton
K <sub>oc</sub>	organic carbon partition coefficient
K <sub>ow</sub>	octanol-water partition coefficient
L	liter
LC	liquid chromatography
LC <sub>50</sub>	lethal concentration, 50% kill
LC <sub>Lo</sub>	lethal concentration, low
LD <sub>50</sub>	lethal dose, 50% kill
LD <sub>Lo</sub>	lethal dose, low
LDH	lactic dehydrogenase
LH	lutinizing hormone
LOAEL	lowest-observed-adverse-effect level
LSE	Levels of Significant Exposure
LT <sub>50</sub>	lethal time, 50% kill
m	meter
MA	<i>trans,trans</i> -muconic acid
MAL	maximum allowable level
mCi	millicurie
MCL	maximum contaminant level

## APPENDIX C

MCLG	maximum contaminant level goal
MF	modifying factor
MFO	mixed function oxidase
mg	milligram
mL	milliliter
mm	millimeter
mmHg	millimeters of mercury
mmol	millimole
mppcf	millions of particles per cubic foot
MRL	Minimal Risk Level
MS	mass spectrometry
NAAQS	National Ambient Air Quality Standard
NAS	National Academy of Science
NATICH	National Air Toxics Information Clearinghouse
NATO	North Atlantic Treaty Organization
NCE	normochromatic erythrocytes
NCEH	National Center for Environmental Health
NCI	National Cancer Institute
ND	not detected
NFPA	National Fire Protection Association
ng	nanogram
NHANES	National Health and Nutrition Examination Survey
NIEHS	National Institute of Environmental Health Sciences
NIOSH	National Institute for Occupational Safety and Health
NIOSHTIC	NIOSH's Computerized Information Retrieval System
NLM	National Library of Medicine
nm	nanometer
nmol	nanomole
NOAEL	no-observed-adverse-effect level
NOES	National Occupational Exposure Survey
NOHS	National Occupational Hazard Survey
NPD	nitrogen phosphorus detection
NPDES	National Pollutant Discharge Elimination System
NPL	National Priorities List
NR	not reported
NRC	National Research Council
NS	not specified
NSPS	New Source Performance Standards
NTIS	National Technical Information Service
NTP	National Toxicology Program
ODW	Office of Drinking Water, EPA
OERR	Office of Emergency and Remedial Response, EPA
OHM/TADS	Oil and Hazardous Materials/Technical Assistance Data System
OPP	Office of Pesticide Programs, EPA
OPPT	Office of Pollution Prevention and Toxics, EPA
OPPTS	Office of Prevention, Pesticides and Toxic Substances, EPA
OR	odds ratio
OSHA	Occupational Safety and Health Administration
OSW	Office of Solid Waste, EPA
OTS	Office of Toxic Substances
OW	Office of Water

## APPENDIX C

OWRS	Office of Water Regulations and Standards, EPA
PAH	polycyclic aromatic hydrocarbon
PBPD	physiologically based pharmacodynamic
PBPK	physiologically based pharmacokinetic
PCE	polychromatic erythrocytes
PEL	permissible exposure limit
pg	picogram
PHS	Public Health Service
PID	photo ionization detector
pmol	picomole
PMR	proportionate mortality ratio
ppb	parts per billion
ppm	parts per million
ppt	parts per trillion
PSNS	pretreatment standards for new sources
RBC	red blood cell
REL	recommended exposure level/limit
RfC	reference concentration
RfD	reference dose
RNA	ribonucleic acid
RQ	reportable quantity
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
SCE	sister chromatid exchange
SGOT	serum glutamic oxaloacetic transaminase
SGPT	serum glutamic pyruvic transaminase
SIC	standard industrial classification
SIM	selected ion monitoring
SMCL	secondary maximum contaminant level
SMR	standardized mortality ratio
SNARL	suggested no adverse response level
SPEGL	Short-Term Public Emergency Guidance Level
STEL	short term exposure limit
STORET	Storage and Retrieval
TD <sub>50</sub>	toxic dose, 50% specific toxic effect
TLV	threshold limit value
TOC	total organic carbon
TPQ	threshold planning quantity
TRI	Toxics Release Inventory
TSCA	Toxic Substances Control Act
TWA	time-weighted average
UF	uncertainty factor
U.S.	United States
USDA	United States Department of Agriculture
USGS	United States Geological Survey
VOC	volatile organic compound
WBC	white blood cell
WHO	World Health Organization

## APPENDIX C

>	greater than
≥	greater than or equal to
=	equal to
<	less than
≤	less than or equal to
%	percent
α	alpha
β	beta
γ	gamma
δ	delta
μm	micrometer
μg	microgram
q <sub>1</sub> *	cancer slope factor
-	negative
+	positive
(+)	weakly positive result
(-)	weakly negative result



## APPENDIX D. INDEX

absorbed dose .....	97
adenocarcinoma .....	49, 57
adrenal gland .....	21, 54, 67, 105
adsorption .....	14, 127, 135, 136
aerobic .....	137
anaerobic .....	126, 137
aspartate aminotransferase (see AST) .....	68
AST (see aspartate aminotransferase) .....	68
bioaccumulation .....	148
bioavailability .....	148
biomarker .....	96, 97, 98, 108, 109, 153, 160
blood cell count .....	53, 66
body weight effects .....	54, 67, 71
breast milk .....	7, 145
burns .....	4, 6, 7, 8, 15, 16, 25, 26, 48, 52, 55, 65, 66, 70, 71, 73, 75, 80, 90, 92, 95, 101, 102, 104, 107
cancer .....	6, 70, 94, 106
carcinogen .....	57, 70, 98
carcinogenic .....	6, 23, 24, 69, 98, 106, 108, 163
carcinogenicity .....	106
carcinoma .....	49, 56, 75
cardiac arrhythmia .....	52
cardiovascular .....	21, 52, 56, 57, 58, 71, 104
cardiovascular effects .....	52, 58, 71, 104
chromosomal aberrations .....	76, 106
death .....	6, 15, 17, 23, 25, 48, 58, 66, 73, 90, 102
deoxyribonucleic acid (see DNA) .....	77
dermal effects .....	16, 17, 54, 73
DNA (see deoxyribonucleic acid) .....	3, 15, 77, 78, 96
dyspnea .....	19, 47, 48, 49, 105, 163
endocrine .....	54, 67, 71, 92, 93
endocrine effects .....	54, 67
erythema .....	65, 74
fertilizer .....	2, 3, 4, 7, 13, 14, 46, 47, 76, 95, 105, 106, 108, 118, 122, 126, 127, 131, 132, 133, 139, 140, 141, 143, 144, 145, 162, 163, 168
fetus .....	7, 56, 93, 106
gastrointestinal effects .....	52, 65, 71
general population .....	14, 18, 70, 96, 106, 127, 143, 146
genotoxic .....	23, 76
genotoxicity .....	106
groundwater .....	95, 128, 131, 136, 137, 142
half-life .....	14, 96, 126, 127, 137
hematological effects .....	53, 66
hepatic effects .....	53, 66
hydrolysis .....	133
hydroxyl radical .....	126, 137
hyperammonemia .....	15, 17, 68, 90, 93, 95, 98, 99
immune system .....	55, 75, 107
immunological .....	23, 55, 67, 75
immunological effects .....	67, 75
irritation .....	6, 8, 16, 18, 19, 26, 46, 47, 79, 95, 97, 99, 102, 104, 105, 163
K <sub>ow</sub> .....	115
LD <sub>50</sub> .....	55

## APPENDIX D

livestock.....	5, 8, 13, 16, 46, 74, 105, 126, 131, 132, 133, 139, 140, 141, 147, 151
manure.....	2, 5, 13, 14, 131, 136, 140, 142, 143, 144, 145, 151
metabolic acidosis.....	21, 57, 58, 66, 104
micronuclei.....	76, 106
milk.....	150, 151
muscarinic receptor.....	90
musculoskeletal effects.....	53, 66
neoplastic.....	49, 57
neurobehavioral.....	93
neurochemical.....	107
neurotransmitter.....	95, 107
nitrate.....	2, 14, 83, 113, 122, 126, 127, 136, 137, 138, 142, 159, 166, 167, 168, 169
nitrite.....	14, 126, 127, 159
nitrogen cycle.....	117, 123, 131, 137, 148
nitrogen fixation.....	117, 123, 126, 134
ocular effects.....	17, 54, 58, 71, 74
pharmacodynamic.....	87
pharmacokinetic.....	87, 88, 89, 90, 94
placenta.....	7
poultry.....	5, 14, 127, 131, 133, 142, 144, 150, 151
pulmonary function.....	16, 18, 19, 26, 46, 47, 102, 105, 163
rate constant.....	137
renal effects.....	15, 21, 53, 66, 73, 104, 105
retention.....	79, 81
solubility.....	16, 73, 90, 101, 113
toxicokinetic.....	23, 109
urea.....	15, 17, 21, 57, 78, 79, 80, 81, 82, 83, 86, 87, 90, 91, 95, 97, 99, 101, 109, 111, 122, 131, 133, 144, 155
vapor phase.....	159
volatility.....	113
volatilization.....	126, 132, 135, 136, 137, 138, 140, 144, 156, 159
weanling.....	58, 65, 66, 67